Unknown

Dataset Information

0

Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase.


ABSTRACT: Resistance to therapeutics such as trimethoprim-sulfamethoxazole has become an increasing problem in strains of methicillin-resistant Staphylococcus aureus (MRSA). Clinically isolated trimethoprim-resistant strains reveal a double mutation, H30N/F98Y, in dihydrofolate reductase (DHFR). In order to develop novel and effective therapeutics against these resistant strains, we evaluated a series of propargyl-linked antifolate lead compounds for inhibition of the mutant enzyme. For the propargyl-linked antifolates, the F98Y mutation generates minimal (between 1.2- and 6-fold) losses of affinity and the H30N mutation generates greater losses (between 2.4- and 48-fold). Conversely, trimethoprim affinity is largely diminished by the F98Y mutation (36-fold) and is not affected by the H30N mutation. In order to elucidate a mechanism of resistance, we determined a crystal structure of a complex of this double mutant with a lead propargyl-linked antifolate. This structure suggests a resistance mechanism consistent both for the propargyl-linked class of antifolates and for trimethoprim that is based on the loss of a conserved water-mediated hydrogen bond.

SUBMITTER: Frey KM 

PROVIDER: S-EPMC2841211 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase.

Frey Kathleen M KM   Lombardo Michael N MN   Wright Dennis L DL   Anderson Amy C AC  

Journal of structural biology 20091221 1


Resistance to therapeutics such as trimethoprim-sulfamethoxazole has become an increasing problem in strains of methicillin-resistant Staphylococcus aureus (MRSA). Clinically isolated trimethoprim-resistant strains reveal a double mutation, H30N/F98Y, in dihydrofolate reductase (DHFR). In order to develop novel and effective therapeutics against these resistant strains, we evaluated a series of propargyl-linked antifolate lead compounds for inhibition of the mutant enzyme. For the propargyl-link  ...[more]

Similar Datasets

| S-EPMC7025792 | biostudies-literature
| S-EPMC2723953 | biostudies-literature
| S-EPMC1195413 | biostudies-literature
| S-EPMC187982 | biostudies-other
| S-EPMC89034 | biostudies-literature
| S-EPMC11223284 | biostudies-literature
| S-EPMC2805538 | biostudies-literature
| S-EPMC2934973 | biostudies-literature
| S-EPMC162857 | biostudies-other
| S-EPMC176980 | biostudies-other